The translational revolution in atopic dermatitis:the paradigm shift from pathogenesis to treatment  

作　　者：Paola Facheris Jane Jeffery Ester Del Duca Emma Guttman-Yassky 

机构地区：[1]Laboratory of Inflammatory Skin Diseases,Department of Dermatology,Icahn School of Medicine at Mount Sinai,New York,NY,USA [2]Humanitas Clinical and Research Center,Department of Dermatology,Rozzano,Milano,Italy [3]Duke University School of Medicine,Durham,NC,USA [4]Department of Dermatology,Icahn School of Medicine at Mount Sinai,New York,NY,USA.

出　　处：《Cellular & Molecular Immunology》2023年第5期448-474,共27页中国免疫学杂志（英文版）

摘　　要：Atopic dermatitis(AD)is the most common inflammatory skin disease,and it is considered a complex and heterogeneous condition.Different phenotypes of AD,defined according to the patient age at onset,race,and ethnic background;disease duration;and other disease characteristics,have been recently described,underlying the need for a personalized treatment approach.Recent advancements in understanding AD pathogenesis resulted in a real translational revolution and led to the exponential expansion of the therapeutic pipeline.The study of biomarkers in clinical studies of emerging treatments is helping clarify the role of each cytokine and immune pathway in AD and will allow addressing the unique immune fingerprints of each AD subset.Personalized medicine will be the ultimate goal of this targeted translational research.In this review,we discuss the changes in the concepts of both the pathogenesis of and treatment approach to AD,highlight the scientific rationale behind each targeted treatment and report the most recent clinical efficacy data.

关 键 词：Atopic dermatitis translational revolution biomarkers ECZEMA 

分 类 号：R751[医药卫生—皮肤病学与性病学]